Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02770014
What this trial is testing

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Who this might be right for
Epidermal Growth Factor ReceptorNon-Small Cell Lung Cancer
Dana-Farber Cancer Institute 43
Early research (Phase 1)Not Yet RecruitingNCT07461727
What this trial is testing

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Who this might be right for
Non-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Not applicableNot Yet RecruitingNCT06786208
What this trial is testing

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Who this might be right for
Non Small Cell Lung Cancer
Henan Cancer Hospital 55
Not applicableStudy completedNCT07213076
What this trial is testing

Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 350
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07038460
What this trial is testing

Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

Who this might be right for
Resectable Non-small Cell Lung Cancer
Wen-zhao ZHONG 134
Not applicableLooking for participantsNCT07028489
What this trial is testing

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
N-Power Medicine 130
Early research (Phase 1)Not Yet RecruitingNCT07842887
What this trial is testing

Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance

Who this might be right for
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Early research (Phase 1)Study completedNCT04479306
What this trial is testing

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+2 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Looking for participantsNCT07774520
What this trial is testing

Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)EGFR Mutant
Samsung Medical Center 1,173
Early research (Phase 1)Study completedNCT02503774
What this trial is testing

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Who this might be right for
Solid Tumors
MedImmune LLC 192
Testing effectiveness (Phase 2)UnknownNCT03749213
What this trial is testing

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

Who this might be right for
EGF-R Positive Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 36
Early research (Phase 1)Looking for participantsNCT07462377
What this trial is testing

EPI-326 in EGFR-mutant NSCLC and HNSCC

Who this might be right for
Epidermal Growth FactorEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene Mutation+12 more
EpiBiologics 110
Testing effectiveness (Phase 2)Study completedNCT02879994
What this trial is testing

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Stage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center 11
Large-scale testing (Phase 3)UnknownNCT03074864
What this trial is testing

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Who this might be right for
Non-small Cell Lung CancerEpidermal Growth Factor Receptor
Guangdong Provincial People's Hospital 90
Not applicableStudy completedNCT06613633
What this trial is testing

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Who this might be right for
Third-generation TKINSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University 4,000
Testing effectiveness (Phase 2)Ended earlyNCT04908956
What this trial is testing

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
ETOP IBCSG Partners Foundation 6
Not applicableEnded earlyNCT02491775
What this trial is testing

Afatinib Genomic Landscape

Who this might be right for
Carcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNon-small Lung Cancer
Washington University School of Medicine 6
Testing effectiveness (Phase 2)UnknownNCT00339586
What this trial is testing

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Who this might be right for
Lung NeoplasmsNon-Small Cell Lung CancerAdenocarcinoma, Bronchiolo-Alveolar
Universitair Ziekenhuis Brussel 40
Very early researchStudy completedNCT03755102
What this trial is testing

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Who this might be right for
EGFR Gene MutationLung CancerLung Cancer Metastatic
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Ended earlyNCT03255083
What this trial is testing

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 13
Next Page